www.fdanews.com/articles/176816-acorda-terminates-development-of-epilepsy-biosimilar
Acorda Terminates Development of Epilepsy Biosimilar
May 26, 2016
Acorda Therapeutics is discontinuing development of a biosimilar to Valeant Pharmaceutical International’s sedative Plumiaz after trials failed to establish bioequivalence.
The company said the data showed “unexpectedly lower nasal mucosa absorption” of the biosimilar in the target patient population — epileptics — than it did in a control group.
Acorda added that it will present the trial data at an unspecified future medical conference while shifting focus to other products in its pipeline.